WebCA-4948 is a novel oral IRAK4 inhibitor of the TLR/myddosome Pathway • Well absorbed; pharmacokinetics are predictable and support BID dosing • Well tolerated; safety profile allows long-term treatment and combination with other active drugs against NHL • Pharmacodynamic analyses demonstrate NFκB inhibition and reduction of cytokine release WebMay 12, 2024 · Curis Reports Updated Data in Two Abstracts for CA-4948 Accepted for Presentation at the European Hematology Association 2024 Virtual Congress /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS),...
Home - Curis, Inc
WebMar 1, 2024 · Figure 2: Pipeline (Source: corporate presentation) CA-4948 goes after IRAK4 (first in class inhibitor) and CI-8993 is a monoclonal antibody first in class antagonist of VISTA (the third of 3 ... WebMay 13, 2024 · Curis, whose market cap now sits at nearly $1.5bn, has a lot riding on CA-4948. Its next most advanced asset is the anti-Vista monoclonal antibody CI-8993, on which phase 1 data is due in the second half of the year. Two further clinical-stage assets are on ice after earlier disappointments. optima foot and ankle bend oregon
Corporate Presentation
WebMar 16, 2024 · As of December 31, 2024, Curis' cash, cash equivalents and investments totaled $183.1 million, which includes net proceeds of $159.1 million from our follow-on public offering in December... WebThis presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform ... NHL CA-4948* IRAK4 IL -1R/TLR altered AML, MDS Immune Checkpoint Inhibitors CA-170* PDL1/VISTA ... Booher et al. ASH 2016 (poster #4184) 4) Data from Curis ... WebNov 5, 2024 · Introduction. CA-4948 is a novel oral small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 is part of the Myddosome signaling pathway, and is essential for signaling downstream of toll-like receptors (TLR) and the interleukin-1 receptor (IL-1R) family in immune cells including B lymphocytes. . optima for guardian ad litem